Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Using Multi-tracer to early diagnosis of therapy-associated cardiotoxicity using multimodality PET/MRI.
In this study investigators evaluated cardiac uptake by different molecular probe such as FDG, FAPI-04 using multimodality PET/MRI. Previous studies have shown that increased cardiac uptake of FDG on PET may be an indicator of myocardial injury after chemotherapy. Cardiac magnetic resonance (CMR) allows for multiparametric evaluation of cardiac morphology, ventricular function, myocardial perfusion, and viability. The combination of PET with MR (PET/MR) is therefore an alternative attractive pairing for diagnostic imaging. The aim of this study is to find noninvasive and effective method for early diagnosis of cardiotoxicity after chemotherapy or immunotherapy
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| therapy group | lymphoma patients planned chemotherapy or immunotherapy scheme | ||
| healthy control group | Inclusion criteria for the controls were no known diseases or syndromes, within the age range from 18 to 35 years. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| SUVR | the ratio of the standardized uptake value(SUVR) of multi-tracer for the heart within each time window to that of the normal tissue such as hepatic blood pool、blood pool and gluteus. | 150 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change Of Mapping Value and LVEF From Baseline | The change of mapping value and left ventricular ejection fraction between the value before treatment and the value after treatment was calculated based on cardiac magnetic resonance | 150 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with malignant tumor after chemotherapy or immunotherapy
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Xuejuan Wang, MD | Contact | 86 010 88196363 | xuejuan_wang@hotmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Zhi Yang, PhD | Peking University Cancer Hospital & Institute | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University Cancer Hospital | Recruiting | Beijing | Beijing Municipality | 100142 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D066126 | Cardiotoxicity |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| D064419 | Chemically-Induced Disorders |
| D011832 | Radiation Injuries |
| D014947 | Wounds and Injuries |